Walleye Trading’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.18M | Sell |
6,600
-7,200
| -52% | -$2.45M | ﹤0.01% | 1652 |
|
|
2025
Q4 | $5.49M | Buy |
13,800
+6,500
| +89% | +$2.88M | 0.01% | 1237 |
|
|
2025
Q3 | $3.33M | Buy |
7,300
+6,300
| +630% | +$2.57M | 0.01% | 1485 |
|
|
2025
Q2 | $326K | Sell |
1,000
-5,300
| -84% | -$1.47M | ﹤0.01% | 2937 |
|
|
2025
Q1 | $1.7M | Buy |
6,300
+4,600
| +271% | +$1.18M | ﹤0.01% | 1728 |
|
|
2024
Q4 | $400K | Sell |
1,700
-3,500
| -67% | -$920K | ﹤0.01% | 2785 |
|
|
2024
Q3 | $1.43M | Buy |
5,200
+1,200
| +30% | +$312K | ﹤0.01% | 1894 |
|
|
2024
Q2 | $972K | Sell |
4,000
-78,500
| -95% | -$12.4M | ﹤0.01% | 2090 |
|
|
2024
Q1 | $12.3M | Sell |
82,500
-13,600
| -14% | -$2.27M | 0.03% | 608 |
|
|
2023
Q4 | $18.4M | Buy |
96,100
+78,700
| +452% | +$13.4M | 0.04% | 478 |
|
|
2023
Q3 | $3.08M | Sell |
17,400
-5,700
| -25% | -$1.09M | 0.01% | 1458 |
|
|
2023
Q2 | $4.39M | Sell |
23,100
-4,500
| -16% | -$892K | 0.01% | 1049 |
|
|
2023
Q1 | $5.53M | Sell |
27,600
-13,900
| -33% | -$2.92M | 0.01% | 976 |
|
|
2022
Q4 | $9.86M | Sell |
41,500
-68,800
| -62% | -$14.7M | 0.03% | 669 |
|
|
2022
Q3 | $22.1M | Buy |
110,300
+36,600
| +50% | +$6.98M | 0.07% | 290 |
|
|
2022
Q2 | $10.7M | Buy |
73,700
+57,600
| +358% | +$8.17M | 0.03% | 569 |
|
|
2022
Q1 | $2.63M | Buy |
16,100
+6,500
| +68% | +$990K | 0.01% | 1467 |
|
|
2021
Q4 | $1.63M | Buy |
9,600
+4,200
| +78% | +$781K | 0.01% | 1819 |
|
|
2021
Q3 | $1.02M | Sell |
5,400
-24,500
| -82% | -$4.6M | ﹤0.01% | 2177 |
|
|
2021
Q2 | $5.07M | Buy |
29,900
+27,900
| +1,395% | +$4.09M | 0.02% | 784 |
|
|
2021
Q1 | $282K | Sell |
2,000
-18,500
| -90% | -$2.78M | ﹤0.01% | 3289 |
|
|
2020
Q4 | $2.66M | Hold |
20,500
| – | – | 0.01% | 1178 |
|
|
2020
Q3 | $2.98M | Sell |
20,500
-1,200
| -6% | -$171K | 0.02% | 870 |
|
|
2020
Q2 | $3.21M | Sell |
21,700
-17,300
| -44% | -$2.33M | 0.02% | 778 |
|
|
2020
Q1 | $4.25M | Buy |
39,000
+10,500
| +37% | +$1.21M | 0.03% | 460 |
|
|
2019
Q4 | $3.28M | Buy |
28,500
+22,100
| +345% | +$2.2M | 0.02% | 850 |
|
|
2019
Q3 | $515K | Sell |
6,400
-11,200
| -64% | -$886K | ﹤0.01% | 2124 |
|
|
2019
Q2 | $1.28M | Buy |
17,600
+11,800
| +203% | +$905K | 0.01% | 1398 |
|
|
2019
Q1 | $542K | Sell |
5,800
-700
| -11% | -$58.5K | ﹤0.01% | 2205 |
|
|
2018
Q4 | $474K | Buy |
6,500
+4,400
| +210% | +$338K | ﹤0.01% | 2522 |
|
|
2018
Q3 | $184K | Sell |
2,100
-4,300
| -67% | -$433K | ﹤0.01% | 3824 |
|
|
2018
Q2 | $630K | Buy |
+6,400
| New | +$635K | ﹤0.01% | 2595 |
|
Other funds holding ALNY
VPM
VCM
Walleye Trading's ALNY Position: Q1 2026 in Review
Walleye Trading reduced its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q1 2026, selling an estimated $987K and leaving 5,756 shares worth $1.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1746.
Walleye Trading first reported a position in ALNY in Q2 2015 and has held it in 25 quarters since. The position peaked at $5.65M in Q3 2022. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Walleye Trading held 5,756 shares of Alnylam Pharmaceuticals worth $1.9M as of Q1 2026.
- Walleye Trading sold 2,901 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $987K.
- Alnylam Pharmaceuticals made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #1746 holding.
- Walleye Trading first reported a position in Alnylam Pharmaceuticals in Q2 2015 and has held it in 25 quarters since.
- Walleye Trading's Alnylam Pharmaceuticals position peaked at $5.65M in Q3 2022.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.